Rite Aid Business Model Canvas

Rite Aid and its PBM Elixir partner with health plans and employer sponsors to design formularies, networks, and cost-containment programs that steer utilization and preferred-script volume. These contracts, across Rite Aid’s network of over 2,000 retail locations, drive pharmacy script volume via preferred status and network placement. Data-sharing enables utilization management and outcomes reporting for millions of members, aligning incentives to lower total cost of care and improve member experience.

Rite Aid leverages manufacturers, wholesalers, PBM Elixir, clinicians and tech partners to support ~2,174 stores and ~69M prescriptions (FY2024), with manufacturer rebates often in double-digit % of net drug cost and >3M immunizations delivered recently. Major wholesalers cover ~85% of US drug distribution, enabling just‑in‑time replenishment and specialty logistics. Integrated IT and last‑mile partners (e.g., Instacart) power e‑commerce, claims and same‑day delivery.

Category planning, planograms, and targeted promotions drive front-end sales by aligning shelf space with high-margin SKUs and impulse buys; demand forecasting and cycle counting cut shrink and expirations through tighter replenishment and SKU rationalization. Vendor-managed inventory and automated reordering raise turns and reduce stockouts, while seasonal and local assortments tailor assortments to community needs and peak demand.

Pharmacists fill ~100M prescriptions annually (2024) with counseling, immunizations and point-of-care testing across ~2,000 stores. Elixir PBM centralizes claims, formularies and rebates to reduce drug spend and steer utilization. Omnichannel fulfillment (app, BOPIS, mail) plus category planning and analytics boost front-end margins and adherence.

Elixir PBM platform combines claims engines, pricing tools, and rebate systems to power payer solutions, supporting Rite Aid’s B2B contracts and formulary management.

Integrated data lakes enable utilization analytics, risk scoring, and outcomes reporting, feeding population health insights; the PBM market exceeded $500 billion in 2024.

Interoperability with eRx and EHR networks improves accuracy and prior authorization workflows, differentiating Rite Aid’s B2B offerings.

Rite Aid's key resources: 2,100+ stores (2024) and retail assets enable omnichannel fulfillment; licensed pharmacists and clinical staff drive vaccinations and care; Elixir PBM and data lakes power payer services and analytics; master supplier and payer contracts underpin margins and working capital.

Combining Elixir with Rite Aid retail aligns incentives to lower total cost and improve outcomes, enabling closed-loop referral and medication synchronization across channels. Closed-loop data boosts formulary execution and adherence programs, driving often low-double-digit percentage improvements in adherence and cost avoidance for sponsors. Members get seamless benefits and access at point-of-care while sponsors gain measurable savings and enhanced reporting.

Rite Aid’s neighborhood footprint (~2,000 stores in 2024) and extended hours/drive-thrus enable fast access to meds, vaccines and testing. High generic substitution (~90% U.S. dispensed prescriptions, FDA 2024) plus PBM rebates (20–40%) and discounts lower patient costs and abandonment. Omnichannel care, Elixir integration and pharmacist-led MTM drive adherence, syncing meds and reducing total sponsor spend.

Dedicated B2B account teams support payers and employers with plan design and optimization, aligning benefit strategies with pharmacy network capabilities. Quarterly business reviews track agreed KPIs and clinical outcomes to drive performance and contract renewals. Custom reporting quantifies clinical and financial impact, while consultative support sustains long-term sponsor relationships.

Face-to-face pharmacist care and wellness+ driven personalization build trust and loyalty across Rite Aid’s ~2,200 stores in 2024; 9 in 10 Americans live within 5 miles of a pharmacy (NCPA). Rewards, SMS/app pushes and automated outreach drive repeat visits and adherence; 90-day fills show ≈+20% adherence. B2B consultative teams and community events deepen sponsor and local relationships.

Rite Aid's central-fill and mail services scale 90-day maintenance fills to reduce patient visits and lower per-fill costs. Home delivery improves access for mobility-limited patients and seniors, while validated cold-chain logistics enable specialty biologic and vaccine shipping. Reliable delivery correlates with adherence gains—studies show up to 20% higher medication possession for 90-day fills—reducing gaps and downstream costs.

Rite Aid’s ~2,100 stores (2024) are primary touchpoints for prescriptions, walk-in care and merchandising; omnichannel (website/app integrated with ~2,000 pharmacies) supports refills and bookings and ties to wellness+ (10M+ members). Central-fill/mail 90-day fills raise adherence up to 20% and lower per-fill costs; phone support and Elixir broker/direct sales extend reach to employers and payors.

Seniors and Medicare beneficiaries (about 58 million adults 65+ in the US in 2024) drive high medication use—averaging four or more prescriptions—and strong vaccine demand. Medicare plan dynamics, with Medicare Advantage enrollment above 50% in 2024, shape network selection and copays. Accessibility, in-pharmacy counseling and home delivery plus caregiver support improve adherence and reduce costly readmissions.

Rite Aid serves ~2,200 retail customers and ~58M seniors/Medicare beneficiaries, plus chronic patients (diabetes ~37.3M) and caregivers; FY2024 net sales ≈ $21.3B. Payers/PBMs drive volume via contracts and MA enrollments >50%. Loyalty, 90-day fills, sync programs and clinical services boost adherence and basket size, shifting mix toward private label and promotion-led SKUs.

Leases, maintenance and energy costs at Rite Aid scale with its ~2,000-store footprint, consuming a meaningful share of occupancy expenses given reported fiscal 2024 net sales near $21.9 billion. Equipment, security systems and waste disposal add fixed overhead per location, raising store-level breakeven. Investment in clinic space and cold-chain (vaccine) infrastructure requires upfront capex and ongoing refrigeration energy. Operational efficiency—scheduling, shrink control—drives leverage and margin uplift.

Drug COGS ~75% of COGS; front-end ~25%; manufacturer rebates offset 4–6% of pharmacy costs; shrink 0.5–1%. Payroll (pharmacists ~$130k, techs ~$36k) plus benefits add ~20–30% to wages. Occupancy and store-level capex scale with ~2,160 stores and FY2024 net sales ~$21.9B; IT, logistics and compliance are material recurring costs.

Elixir earns PBM administrative fees for claims processing, formulary management, and clinical programs and, as of 2024, also captures performance-based payments tied to clinical and cost outcomes. Network contracting and rebate management generate incremental revenue, while multi-year client contracts provide more predictable cash flows for Rite Aid’s PBM segment.

Rite Aid generated ~$21.6B net sales in fiscal 2024, driven by prescription reimbursements (net reduced by DIR fees/clawbacks), higher-margin front‑of‑store sales and expanding clinical services. Specialty and mail-order captured material value (specialty ≈55% of US drug spend, IQVIA 2024), while Elixir PBM adds administrative and performance-based fees and recurring contract revenue.